Tag Archives: investing

EU Webinar Series: From Discovery to Decision Making Early-Stage Life Science Legible to Capital 

3 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s EU-focused webinar series, From Discovery to Decision: Making Early-Stage Life Science Legible to Capital, continues this week with Session III. Recordings of the first two sessions are available for those who would like to revisit the insights shared by active investors shaping early-stage healthcare financing.

This series examines a central question for early-stage companies: why strong science alone is not enough to secure capital, and how founders can structure development to become legible to investors.

Session I

Why Solid Science Fails to Translate Before Capital Even Considers It

Hosted by Richard Berenson, Managing Partner, Venzyme Catalyst

Watch the recording:
https://youtu.be/ODbukG6cjNM?si=9lj-BGKRhv2wJISW

In Session I, Richard Berenson offered a candid investor perspective on why many early-stage assets stall before diligence begins. He emphasized that the issue is often not a shortage of capital, but a failure of translation.

Scientific merit alone does not make an opportunity investable. Investors must see clarity around risk reduction, defined milestones, regulatory trajectory, and capital deployment strategy. Companies that struggle to articulate this framework may be filtered out long before meaningful evaluation takes place.

The discussion reframed from fundraising challenges as structural alignment issues rather than capital scarcity.

Session II

Legibility, Signal, and the Real Work Between Seed and Series B

Hosted by Karim Galzhar, Partner, OKG Capital

Watch the recording:
https://youtu.be/Dak112sslq4?si=9MpLvecop5Jxw4_E

Session II built on this foundation with a deeper examination of how investors form conviction between Seed and Series B.

Karim Galzhar outlined what global investors require to underwrite early-stage risk. Signals are formed across scientific validation, regulatory planning, commercial strategy, and disciplined capital use. Data alone does not create signals. Structured progress and stage-appropriate positioning.

The session highlighted how companies can unintentionally dilute signals by engaging the wrong forums too early or by misaligning fundraising expectations with development readiness.

Session III — This Wednesday

Partnering Is Not Exposure. It Is Filtration

Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET

Session III will feature Dennis Ford, Founder & CEO of Life Science Nation and creator of the RESI Conference Series, alongside Gregory Mannix, VP, International Business Development, Life Science Nation.

This session confronts a simple truth: great science does not raise capital, signal does. We will examine how investors actually price risk, why fundraising must be run as a disciplined global campaign, and how legibility turns complex science into an investable story.

We will also address a costly mistake: engaging the wrong partnering events and the wrong investors too early. Not every conference, forum, or investor fits every stage of development. Success requires selecting the right venues, building a stage-appropriate global target list, and engaging partners who are structurally aligned with your product. The goal is to replace activity with real transaction momentum.

Registration for Session III is open: https://us02web.zoom.us/webinar/register/WN_oe499TEOQGmrSnoAzNr1yw#/registration

Register for RESI Europe

Tags: , , , , , , , , , ,

Hot Investor Mandate: Family Office Backed Firm Seeks to Invest in Therapeutics, Especially Rare Diseases and Areas of Unmet Medical Need

3 Mar

The firm is a family-run investment and commercialization vehicle focused on early-stage life sciences and technology opportunities. The firm is flexible in structuring transactions, with prior investments ranging from minority participation in financing rounds to in-licensing entire therapeutic programs.  

The firm specializes in therapeutic opportunities, with a particular emphasis on rare diseases. The firm prioritizes indications where the pathophysiology is well understood, the development pathway is straightforward, and there is a clearly defined unmet medical need. The firm is also attracted to opportunities that are de-risked, including reformulation strategies and drug repurposing approaches.  

From a company and management team perspective, the firm has a strong preference for experienced leadership teams with proven track records of value creation and execution.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border VC Firm With New Early-Stage Fund Invests in Biotech, Medtech, and Enabling Platforms in North America and Asia

3 Mar

 
 The firm is a global venture capital firm headquartered in Asia, with investment activity spanning Asia and the United States. The firm has raised multiple funds and recently launched a dedicated vehicle focused on biotechnology and medical technology innovation. The firm invests from Seed through early-growth stages and has backed a broad portfolio of healthcare companies. The firm deploys equity capital and works closely with founders to support global expansion, leveraging cross-border operating presence and networks across Asia and North America.  

The firm focuses on biotechnology, medical technology, and enabling platforms addressing major unmet needs in human health. The firm invests in breakthrough science and engineering-driven innovation, including therapeutics, medtech devices, diagnostics, digital health, research tools, and frontier health technologies. The firm follows a cross-border strategy that sources scientific breakthroughs from both Eastern and Western ecosystems, particularly opportunities facing market fragmentation or structural barriers that may limit global scale. The firm emphasizes companies with strong scientific foundations, differentiated clinical or technical positioning, and opportunities that can benefit from accelerated development and market access through Asian clinical, talent, and supply chain ecosystems.  

From a company and management team perspective, the firm partners with founders who demonstrate deep scientific or medical expertise, strong execution capability, and readiness for global expansion. The firm actively supports teams through hands-on venture building and provides access to clinical resources, supply networks, operating talent, and cross-border strategic guidance. The firm collaborates with companies from early stages through exit, aligning with founders to pursue global outcomes including IPOs, M&A, and strategic partnerships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office Invests in Pre-Clinical and Clinical Stage Biotech and Tech-Enabled Healthcare Technologies in North America

3 Mar

A family office invests in both private and public life science and healthcare companies. The firm typically writes six-figure checks for companies approaching clinical development. While historically focused on North America, the firm remains open to evaluating opportunities globally. The firm invests across therapeutics, diagnostics, digital health, and medical devices.  

The firm is generally disease-agnostic, with particular interest in ophthalmology, inflammation, and dermatology. The firm is also increasingly exploring opportunities at the intersection of technology and healthcare, including AI-enabled platforms that enhance patient management and diagnostic workflows. Although oncology is not a core focus, the firm may selectively evaluate certain indications.  

From a stage perspective, the firm reviews opportunities as early as pre-IND and generally prefers programs through Phase II development. The firm seeks evidence of technical and regulatory de-risking, including proof-of-concept data, early efficacy signals, and clearly defined regulatory pathways.  

The firm does not impose strict requirements on company or management team composition but values teams that demonstrate regulatory expertise and the ability to execute within clinical and compliance-driven environments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Biopharmaceutical Seeks Strategic Investment and Partnering Opportunities With Early-Stage Therapeutics Assets

3 Mar

The firm is a publicly listed global biopharmaceutical company headquartered in Asia with a strong presence across major international markets. The firm is recognized for its capabilities in large-scale biologics development and manufacturing and has built a substantial commercial footprint worldwide. The firm pursues external innovation through equity investments, research collaborations, and in-licensing arrangements to strengthen and diversify its pipeline.  

The firm operates broadly across therapeutics and biopharmaceutical innovation, with established expertise in antibody-based medicines, follow-on biologics, and next-generation biologic platforms. The firm continues to expand into novel therapeutic programs across immunology, oncology, infectious diseases, and other high-need areas. In addition to maintaining a portfolio of established biologic products, the firm is actively enhancing its innovative pipeline through internal research, strategic partnerships, and selective in-licensing of differentiated biologic assets, including immune-modulating therapies and advanced antibody formats. The firm is open to opportunities across development stages, with interest in early and mid-stage programs.  

The firm seeks partnerships that align with its long-term biologics strategy and leverage its global development, regulatory, and manufacturing infrastructure. The firm evaluates opportunities based on strong scientific rationale, differentiated clinical positioning, scalable manufacturing feasibility, and global market potential. The firm prefers to collaborate with teams that demonstrate rigorous data generation, defensible intellectual property, and the operational capability to execute international development and commercialization strategies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee

24 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

As RESI Europe 2026 approaches, one of the most important milestones is just ahead. On March 2, the partnering platform officially opens, giving registered attendees the opportunity to begin requesting and scheduling meetings with investors, strategic partners, and fellow innovators across the global life science ecosystem.

Below are two key updates to plan around.

Partnering Opens March 2: Secure Meetings Early

Partnering is the foundation of every RESI conference. From the moment the platform opens, companies can review attendee profiles, identify aligned investors and strategic partners, and begin building a focused meeting schedule.

The earlier you register and enter the platform, the more time you can:

  • Refine your profile and messaging
  • Target investors who match your stage and sector
  • Send thoughtful, customized meeting requests
  • Fill your calendar with high-value conversations

RESI Europe is structured to help early-stage companies connect efficiently with active investors. Through curated matchmaking and detailed attendee profiles, startups can prioritize fit over volume. Beyond pre-scheduled 1-to-1 meetings, the conference also creates opportunities for ad hoc introductions and follow-up discussions that often extend well beyond the event itself.

To help attendees prepare, Life Science Nation will host a dedicated RESI Europe Partnering Tutorial on Tuesday, March 3 at 10:00 AM Eastern Time (US and Canada). Understanding the RESI partnering system and using it to its maximum capabilities can make a significant difference in a company’s success at RESI Europe 2026. During this session, LSN staff will walk participants through how to navigate the platform, identify investors and strategic partners who are the best fit, manage outreach effectively, implement a strong follow-up strategy, and leverage the full range of conference content to strengthen their overall partnering experience. You can register for the webinar here.

Complimentary Second Attendee with 5-Day Registration

To help companies maximize their partnering coverage, RESI Europe 2026 is offering a complimentary second attendee pass with a standard 5-day registration.

Bringing a colleague allows your team to:

  • Cover more investor meetings
  • Attend concurrent sessions
  • Expand networking reach across the event
  • Ensure no key conversation is missed

This offer is not valid for Virtual or Audience Access passes. Attendees who registered for a 5-day ticket on or before February 22 may contact salescore@lifesciencenation.com to add a second attendee.

With partnering opening March 2 and expanded registration value now available, now is the time to secure your place. Enter the partnering system early, prepare strategically, and position your company to make the most of RESI Europe 2026.

Register for RESI Europe

Tags: , , , , , , , , , ,

RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment 

24 Feb

By Sougato Das, President and COO, LSN

Sougato-Das

RESI Europe is one of the major pieces in the puzzle of how to stimulate biotech and life science investing in Europe. In addition to the largest investor partnering conference coming to Lisbon on March 23, the European Life Sciences Coalition (ELSC), a new alliance of major venture capital firms advocating for increased funding and policy support for Europe’s biotech sector, has launched. The coalition includes leading investors such as Novo Holdings, Sofinnova Partners, Forbion, and Omega Funds, representing a combined €24 billion in life sciences assets and involvement in more than 1,400 companies. It launched in association with Invest Europe, whose 650+ members manage 60% of European private equity and venture capital, totaling €1.25 trillion in assets. Alongside major initiatives like the European Innovation Council, whose funded companies enjoy 50% reimbursement for attending RESI Europe, the ELSC hopes to bring new energy to the entrepreneurial sector of life sciences. 

Despite Europe’s strong pharmaceutical presence—five of the world’s top 10 pharma companies by revenue are European—and the industry supporting 29 million EU jobs, the region struggles to scale and retain biotech and life science innovation. The coalition highlights several challenges: 

  • Fragmented capital markets 
  • Declining numbers of specialized VC firms 
  • Regulatory hurdles 
  • Limited access to growth capital 

Europe accounts for only 7% of global venture capital, compared to 63% for the U.S. and 14% for China. Fortunately, events like RESI Europe create a forum where nearly all of the firms representing the 7% are available for partnering, acting as a facilitator to stimulate European life science investment. The dire need for this is underscored by the fact that nearly all EU-based biotechs that went public last year chose to list outside the EU, highlighting concerns about capital flight. 

ELSC members joined the coalition to help reverse these trends, emphasizing the need for sustained funding from both public and private sources across all stages of life sciences development. Industry leaders argue that Europe must increase investment in innovative medicines and treatments, and create supportive policy frameworks and forums, like RESI Europe, or risk losing access to cutting-edge therapies. The ELSC aims to work with policymakers and leverage Invest Europe’s network to strengthen Europe’s ability to fund and scale biotech innovation domestically.

Register for RESI Europe

Tags: , , , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →